# US 2016/0235798 A1 · Methods for treatment of m-tor inhibitor-associated stomatitis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0235798 A1
- Document ID: US20160235798A1
- Status: Published application
- Kind: A1
- Application number: 15/029,255
- Filed: 2014-10-14
- Published: 2016-08-18
- Earliest claimed: 2013-10-14
- Assignees: Izun Pharmaceuticals Corp.
- Applicants: Izun Pharmaceuticals Corp.
- Inventors: William Z. LEVINE; Gabriel Jay NUSSBAUM
- Web page: https://patentgrep.com/patent/US20160235798A1

## CPC

- A61K 36/28: Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K 9/006: {Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays}
- A61K 31/00: Medicinal preparations containing organic active ingredients
- A61K 31/436: the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
- A61K 36/185: Magnoliopsida (dicotyledons)
- A61K 36/23: Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61P 1/02: Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Embodiments of the invention relate to a method for the treatment of mlAS or prevention of symptoms associated with mlAS in a patient in need thereof comprising administering to a patient in need thereof an amount of a composition comprising extracts of the plant species Sambucus nigra, Echinacea purpurea, and Centella asiatica. Optionally the ratio of Sambucus nigra, Echinacea purpurea and Centella asiatica is about 7:1:2. Further embodiments relate to use of extracts of the plant species Sambucus nigra, Echinacea purpurea, and Centella asiatica for the manufacture of a medicament for the treatment of mlAS or prevention of symptoms associated with mlAS in a patient in need thereof.

## Claims

### Claim 1

A method for treatment of mIAS or prevention of symptoms associated with mIAS comprising administering an amount of a composition comprising extracts of the plant species Sambucus nigra, Echinacea purpurea, and Centella asiatica to a patient in need thereof.

### Claim 2 (depends on 1)

The method according to claim 1 wherein the ratio of Sambucus nigra, Echinacea purpurea and Centella asiatica is about 7:1:2.

### Claim 3 (depends on 1)

The method according to claim 1 wherein the patient is receiving an mTOR inhibitor treatment.

### Claim 4 (depends on 3)

The method according to claim 3 wherein the patient is receiving an mTOR inhibitor treatment for cancer or organ transplantation.

### Claim 5 (depends on 1)

The method according to claim 1 wherein the composition is in the form of an oral rinse.

### Claim 6 (depends on 1)

The method according to claim 1 wherein the composition is in the form of an oral patch.

### Claim 7 (depends on 1)

The method according to claim 1 wherein the composition is administered to the patient before appearance of mIAS symptoms.

### Claim 8 (depends on 1)

The method according to claim 1 wherein the composition is administered to the patient after appearance of a mIAS symptom.

### Claim 9 (depends on 1)

The method according to claim 1 wherein the mTOR inhibitor and the composition are administered in combination.

### Claim 10 (depends on 1)

The method according to claim 1 wherein the composition is administered in an amount of 1 mg and 1.5 g of extract per day.

### Claim 11 (depends on 10)

The method according to claim 10 wherein the composition is administered in an amount of 625 mg of extract per day.

### Claim 12 (depends on 10)

The method according to claim 10 wherein the composition is administered in an amount of 450 mg of extract per day.

### Claim 13 (depends on 10)

The method according to claim 10 wherein the composition is administered in an amount of 900 mg of extract per day.

### Claim 14 (depends on 1)

The method according to claim 1 wherein the composition is administered in an amount in which TIMP-3 levels are increased in the patient.

### Claim 15 (depends on 1)

The method according to claim 1 wherein the composition further comprises at least one pharmaceutically acceptable excipient.

### Claim 16 (depends on 5)

The method according to claim 5 wherein the composition further comprises propylene glycol.

### Claim 17 (depends on 16)

The method according to claim 16 wherein the weight ratio between the plant extract and propylene glycol is about 1 to 4.

### Claim 18 (depends on 3)

The method according to claim 3 wherein the mTOR inhibitor is selected from the group consisting of: rapamycin, rapamycin analogs, temsirolimus, everolimus, ridaforolimus, sirolimus and deforolimus.

### Claim 19 (depends on 5)

The method according to claim 5 wherein the composition comprises about 0.5% to about 2% plant extract.

### Claim 20 (depends on 19)

The method according to claim 19 wherein the composition comprises about 1% plant extract.

### Claim 21

(canceled)
